EA006488B1 - Пептид, композиция для перорального введения, набор (варианты), способ уменьшения интенсивности симптома атеросклероза (варианты) и способ облегчения или предупреждения коронарного осложнения у млекопитающего (варианты) - Google Patents

Info

Publication number

EA006488B1

EA006488B1 EA200300289A EA200300289A EA006488B1 EA 006488 B1 EA006488 B1 EA 006488B1 EA 200300289 A EA200300289 A EA 200300289A EA 200300289 A EA200300289 A EA 200300289A EA 006488 B1 EA006488 B1 EA 006488B1

Authority

EA

Eurasian Patent Office

Prior art keywords

peptide

group

peptides

amino acids

atherosclerosis

Prior art date

2000-08-24

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 666
• 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 87
• 208000024891 symptom Diseases 0.000 title claims abstract description 55
• 238000000034 method Methods 0.000 title claims description 111
• 239000000203 mixture Substances 0.000 title claims description 39
• 241000124008 Mammalia Species 0.000 title claims description 14
• 230000000116 mitigating effect Effects 0.000 title description 3
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 272
• -1 9-fluorenacetyl group Chemical group 0.000 claims description 90
• 235000001014 amino acid Nutrition 0.000 claims description 89
• 150000001413 amino acids Chemical class 0.000 claims description 82
• 125000006239 protecting group Chemical group 0.000 claims description 82
• 108090000623 proteins and genes Proteins 0.000 claims description 43
• 239000007924 injection Substances 0.000 claims description 42
• 238000002347 injection Methods 0.000 claims description 42
• 102000004169 proteins and genes Human genes 0.000 claims description 42
• 235000018102 proteins Nutrition 0.000 claims description 40
• 150000001408 amides Chemical class 0.000 claims description 34
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 31
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 29
• 229920001184 polypeptide Polymers 0.000 claims description 26
• 239000000463 material Substances 0.000 claims description 25
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 25
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
• 125000000217 alkyl group Chemical group 0.000 claims description 19
• 238000002360 preparation method Methods 0.000 claims description 19
• 235000008206 alpha-amino acids Nutrition 0.000 claims description 18
• 206010048998 Acute phase reaction Diseases 0.000 claims description 17
• 230000004658 acute-phase response Effects 0.000 claims description 17
• 150000001371 alpha-amino acids Chemical class 0.000 claims description 17
• 239000003814 drug Substances 0.000 claims description 17
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
• 239000002253 acid Substances 0.000 claims description 15
• 210000002966 serum Anatomy 0.000 claims description 15
• 229940079593 drug Drugs 0.000 claims description 14
• 239000007928 intraperitoneal injection Substances 0.000 claims description 14
• 125000004432 carbon atom Chemical group C* 0.000 claims description 12
• 239000000945 filler Substances 0.000 claims description 11
• 102000011767 Acute-Phase Proteins Human genes 0.000 claims description 10
• 108010062271 Acute-Phase Proteins Proteins 0.000 claims description 10
• 230000001154 acute effect Effects 0.000 claims description 10
• 125000000539 amino acid group Chemical group 0.000 claims description 9
• 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims description 9
• 201000010099 disease Diseases 0.000 claims description 8
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
• 206010061218 Inflammation Diseases 0.000 claims description 7
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 7
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
• 230000004054 inflammatory process Effects 0.000 claims description 7
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 7
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 6
• 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims description 6
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
• 210000000056 organ Anatomy 0.000 claims description 6
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 6
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
• 208000036142 Viral infection Diseases 0.000 claims description 5
• 150000007513 acids Chemical class 0.000 claims description 5
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
• 230000000144 pharmacologic effect Effects 0.000 claims description 5
• 230000004044 response Effects 0.000 claims description 5
• 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 5
• 230000009385 viral infection Effects 0.000 claims description 5
• 208000035143 Bacterial infection Diseases 0.000 claims description 4
• 208000001132 Osteoporosis Diseases 0.000 claims description 4
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
• 230000028709 inflammatory response Effects 0.000 claims description 4
• WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical group [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 claims description 3
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims description 3
• 108700028909 Serum Amyloid A Proteins 0.000 claims description 3
• 102000054727 Serum Amyloid A Human genes 0.000 claims description 3
• 206010002906 aortic stenosis Diseases 0.000 claims description 3
• 239000003112 inhibitor Substances 0.000 claims description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
• 208000030507 AIDS Diseases 0.000 claims description 2
• 208000024827 Alzheimer disease Diseases 0.000 claims description 2
• 108010074051 C-Reactive Protein Proteins 0.000 claims description 2
• 102100032752 C-reactive protein Human genes 0.000 claims description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
• 206010017533 Fungal infection Diseases 0.000 claims description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
• 206010024229 Leprosy Diseases 0.000 claims description 2
• 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 claims description 2
• 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 claims description 2
• 208000000112 Myalgia Diseases 0.000 claims description 2
• 208000031888 Mycoses Diseases 0.000 claims description 2
• 208000025747 Rheumatic disease Diseases 0.000 claims description 2
• 206010039710 Scleroderma Diseases 0.000 claims description 2
• 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 2
• 208000027866 inflammatory disease Diseases 0.000 claims description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
• 230000000552 rheumatic effect Effects 0.000 claims description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
• 201000008827 tuberculosis Diseases 0.000 claims description 2
• DNVJGJUGFFYUPT-UHFFFAOYSA-N 9h-fluorene-9-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)C3=CC=CC=C3C2=C1 DNVJGJUGFFYUPT-UHFFFAOYSA-N 0.000 claims 2
• 102000003886 Glycoproteins Human genes 0.000 claims 2
• 108090000288 Glycoproteins Proteins 0.000 claims 2
• HTPXFGUCAUTOEL-UHFFFAOYSA-N 9h-fluorene-1-carboxylic acid Chemical group C1C2=CC=CC=C2C2=C1C(C(=O)O)=CC=C2 HTPXFGUCAUTOEL-UHFFFAOYSA-N 0.000 claims 1
• 108010088751 Albumins Proteins 0.000 claims 1
• 102000009027 Albumins Human genes 0.000 claims 1
• 102100040214 Apolipoprotein(a) Human genes 0.000 claims 1
• 108010075016 Ceruloplasmin Proteins 0.000 claims 1
• 102100023321 Ceruloplasmin Human genes 0.000 claims 1
• 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 1
• 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 1
• 108090000955 Complement C2 Proteins 0.000 claims 1
• 102000004381 Complement C2 Human genes 0.000 claims 1
• 108010028778 Complement C4 Proteins 0.000 claims 1
• 108010027644 Complement C9 Proteins 0.000 claims 1
• 102000000989 Complement System Proteins Human genes 0.000 claims 1
• 101710137943 Complement control protein C3 Proteins 0.000 claims 1
• 102000003712 Complement factor B Human genes 0.000 claims 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
• 206010014824 Endotoxic shock Diseases 0.000 claims 1
• 108010049003 Fibrinogen Proteins 0.000 claims 1
• 102000008946 Fibrinogen Human genes 0.000 claims 1
• 102000014702 Haptoglobin Human genes 0.000 claims 1
• 108050005077 Haptoglobin Proteins 0.000 claims 1
• 102000013271 Hemopexin Human genes 0.000 claims 1
• 108010026027 Hemopexin Proteins 0.000 claims 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
• 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
• 102000009112 Mannose-Binding Lectin Human genes 0.000 claims 1
• 108010087870 Mannose-Binding Lectin Proteins 0.000 claims 1
• 208000030852 Parasitic disease Diseases 0.000 claims 1
• 102000010752 Plasminogen Inactivators Human genes 0.000 claims 1
• 108010077971 Plasminogen Inactivators Proteins 0.000 claims 1
• 108010071690 Prealbumin Proteins 0.000 claims 1
• 102000007584 Prealbumin Human genes 0.000 claims 1
• 101710132633 Protein C5 Proteins 0.000 claims 1
• 101710136899 Replication enhancer protein Proteins 0.000 claims 1
• 101710089766 Ribonuclease P protein component Proteins 0.000 claims 1
• 206010040047 Sepsis Diseases 0.000 claims 1
• 206010040070 Septic Shock Diseases 0.000 claims 1
• 102000019197 Superoxide Dismutase Human genes 0.000 claims 1
• 108010012715 Superoxide dismutase Proteins 0.000 claims 1
• 102000004338 Transferrin Human genes 0.000 claims 1
• 108090000901 Transferrin Proteins 0.000 claims 1
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
• 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
• 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 1
• 102000023732 binding proteins Human genes 0.000 claims 1
• 108091008324 binding proteins Proteins 0.000 claims 1
• 230000032770 biofilm formation Effects 0.000 claims 1
• 229940012952 fibrinogen Drugs 0.000 claims 1
• 229960002897 heparin Drugs 0.000 claims 1
• 229920000669 heparin Polymers 0.000 claims 1
• 239000007927 intramuscular injection Substances 0.000 claims 1
• 238000010255 intramuscular injection Methods 0.000 claims 1
• 210000000265 leukocyte Anatomy 0.000 claims 1
• 229910052749 magnesium Inorganic materials 0.000 claims 1
• 239000011777 magnesium Substances 0.000 claims 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
• NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 1
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
• 239000002797 plasminogen activator inhibitor Substances 0.000 claims 1
• 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
• 239000007929 subcutaneous injection Substances 0.000 claims 1
• 238000010254 subcutaneous injection Methods 0.000 claims 1
• 208000011580 syndromic disease Diseases 0.000 claims 1
• 239000012581 transferrin Substances 0.000 claims 1
• 239000012588 trypsin Substances 0.000 claims 1
• 108010047303 von Willebrand Factor Proteins 0.000 claims 1
• 102100036537 von Willebrand factor Human genes 0.000 claims 1
• 229960001134 von willebrand factor Drugs 0.000 claims 1
• 150000008574 D-amino acids Chemical class 0.000 abstract 1
• 241000699670 Mus sp. Species 0.000 description 150
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 113
• 229940024606 amino acid Drugs 0.000 description 97
• 150000002632 lipids Chemical class 0.000 description 69
• 210000001616 monocyte Anatomy 0.000 description 61
• 210000002381 plasma Anatomy 0.000 description 57
• 210000004027 cell Anatomy 0.000 description 55
• 241000699666 Mus <mouse, genus> Species 0.000 description 53
• 230000003399 chemotactic effect Effects 0.000 description 50
• 241001465754 Metazoa Species 0.000 description 49
• 230000000694 effects Effects 0.000 description 49
• 235000012000 cholesterol Nutrition 0.000 description 46
• 230000015572 biosynthetic process Effects 0.000 description 44
• 230000003647 oxidation Effects 0.000 description 38
• 238000007254 oxidation reaction Methods 0.000 description 38
• 150000003904 phospholipids Chemical class 0.000 description 38
• 230000000923 atherogenic effect Effects 0.000 description 36
• 239000002953 phosphate buffered saline Substances 0.000 description 35
• 239000000523 sample Substances 0.000 description 35
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 34
• 235000013305 food Nutrition 0.000 description 32
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
• 230000006378 damage Effects 0.000 description 29
• 230000001965 increasing effect Effects 0.000 description 27
• 102000004895 Lipoproteins Human genes 0.000 description 26
• 108090001030 Lipoproteins Proteins 0.000 description 26
• 210000004369 blood Anatomy 0.000 description 26
• 239000008280 blood Substances 0.000 description 26
• 229950004354 phosphorylcholine Drugs 0.000 description 23
• 108020003175 receptors Proteins 0.000 description 22
• 102000005962 receptors Human genes 0.000 description 22
• 235000004279 alanine Nutrition 0.000 description 21
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 20
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 20
• 239000000243 solution Substances 0.000 description 20
• 238000011282 treatment Methods 0.000 description 20
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 19
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
• 210000004185 liver Anatomy 0.000 description 18
• 238000003786 synthesis reaction Methods 0.000 description 18
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 17
• 230000004913 activation Effects 0.000 description 17
• 238000004458 analytical method Methods 0.000 description 17
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 16
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 16
• 230000003902 lesion Effects 0.000 description 16
• 239000012071 phase Substances 0.000 description 16
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 16
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 15
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 15
• 238000012360 testing method Methods 0.000 description 15
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 15
• 239000004474 valine Substances 0.000 description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 14
• 230000007423 decrease Effects 0.000 description 14
• 239000002356 single layer Substances 0.000 description 14
• 230000007704 transition Effects 0.000 description 14
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 13
• 108010010234 HDL Lipoproteins Proteins 0.000 description 13
• 102000015779 HDL Lipoproteins Human genes 0.000 description 13
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 13
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 13
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 13
• 239000013543 active substance Substances 0.000 description 13
• 235000003704 aspartic acid Nutrition 0.000 description 13
• 239000002585 base Substances 0.000 description 13
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 13
• 238000004422 calculation algorithm Methods 0.000 description 13
• 238000006243 chemical reaction Methods 0.000 description 13
• 230000035605 chemotaxis Effects 0.000 description 13
• 238000003501 co-culture Methods 0.000 description 13
• 238000002474 experimental method Methods 0.000 description 13
• 235000013922 glutamic acid Nutrition 0.000 description 13
• 239000004220 glutamic acid Substances 0.000 description 13
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 13
• 229960000310 isoleucine Drugs 0.000 description 13
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
• 208000006011 Stroke Diseases 0.000 description 12
• 230000003143 atherosclerotic effect Effects 0.000 description 12
• 230000027455 binding Effects 0.000 description 12
• 239000000306 component Substances 0.000 description 12
• 238000011161 development Methods 0.000 description 12
• 238000006467 substitution reaction Methods 0.000 description 12
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
• 239000004472 Lysine Substances 0.000 description 11
• 230000000903 blocking effect Effects 0.000 description 11
• 239000000872 buffer Substances 0.000 description 11
• 230000003993 interaction Effects 0.000 description 11
• 238000004519 manufacturing process Methods 0.000 description 11
• 229920000642 polymer Polymers 0.000 description 11
• 102000006996 Aryldialkylphosphatase Human genes 0.000 description 10
• 108010008184 Aryldialkylphosphatase Proteins 0.000 description 10
• 238000010521 absorption reaction Methods 0.000 description 10
• 150000002148 esters Chemical class 0.000 description 10
• 230000007717 exclusion Effects 0.000 description 10
• 239000002502 liposome Substances 0.000 description 10
• 230000014759 maintenance of location Effects 0.000 description 10
• 238000005259 measurement Methods 0.000 description 10
• 230000002829 reductive effect Effects 0.000 description 10
• 239000004475 Arginine Substances 0.000 description 9
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 235000014113 dietary fatty acids Nutrition 0.000 description 9
• 229930195729 fatty acid Natural products 0.000 description 9
• 239000000194 fatty acid Substances 0.000 description 9
• 150000004665 fatty acids Chemical class 0.000 description 9
• 208000015181 infectious disease Diseases 0.000 description 9
• 238000002955 isolation Methods 0.000 description 9
• 230000001681 protective effect Effects 0.000 description 9
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 8
• 102000013918 Apolipoproteins E Human genes 0.000 description 8
• 108010025628 Apolipoproteins E Proteins 0.000 description 8
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• 230000008859 change Effects 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• 238000004128 high performance liquid chromatography Methods 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 230000028550 monocyte chemotaxis Effects 0.000 description 8
• 238000010647 peptide synthesis reaction Methods 0.000 description 8
• 239000011347 resin Substances 0.000 description 8
• 229920005989 resin Polymers 0.000 description 8
• 150000003839 salts Chemical class 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 239000007790 solid phase Substances 0.000 description 8
• BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 7
• 239000004471 Glycine Substances 0.000 description 7
• 108010007622 LDL Lipoproteins Proteins 0.000 description 7
• 102000007330 LDL Lipoproteins Human genes 0.000 description 7
• 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 7
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 7
• 239000004473 Threonine Substances 0.000 description 7
• 230000004071 biological effect Effects 0.000 description 7
• 239000000969 carrier Substances 0.000 description 7
• 208000029078 coronary artery disease Diseases 0.000 description 7
• 238000009826 distribution Methods 0.000 description 7
• 230000002209 hydrophobic effect Effects 0.000 description 7
• 239000010410 layer Substances 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 239000007800 oxidant agent Substances 0.000 description 7
• 239000007787 solid Substances 0.000 description 7
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
• 102000007592 Apolipoproteins Human genes 0.000 description 6
• 108010071619 Apolipoproteins Proteins 0.000 description 6
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
• 102400001133 Neuropeptide-glutamic acid-isoleucine Human genes 0.000 description 6
• 101800000397 Neuropeptide-glutamic acid-isoleucine Proteins 0.000 description 6
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
• 210000000709 aorta Anatomy 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 239000000539 dimer Substances 0.000 description 6
• 235000019441 ethanol Nutrition 0.000 description 6
• 206010022000 influenza Diseases 0.000 description 6
• 238000001802 infusion Methods 0.000 description 6
• 208000014674 injury Diseases 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 230000003278 mimic effect Effects 0.000 description 6
• 239000000178 monomer Substances 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 239000002245 particle Substances 0.000 description 6
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 238000004007 reversed phase HPLC Methods 0.000 description 6
• 210000003491 skin Anatomy 0.000 description 6
• 210000002784 stomach Anatomy 0.000 description 6
• 239000006228 supernatant Substances 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• 206010002091 Anaesthesia Diseases 0.000 description 5
• 102000005666 Apolipoprotein A-I Human genes 0.000 description 5
• 108010059886 Apolipoprotein A-I Proteins 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 241000712431 Influenza A virus Species 0.000 description 5
• 239000000654 additive Substances 0.000 description 5
• 230000037005 anaesthesia Effects 0.000 description 5
• 239000002876 beta blocker Substances 0.000 description 5
• 229940097320 beta blocking agent Drugs 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 238000005352 clarification Methods 0.000 description 5
• 239000003636 conditioned culture medium Substances 0.000 description 5
• 239000006071 cream Substances 0.000 description 5
• 230000001186 cumulative effect Effects 0.000 description 5
• 210000002889 endothelial cell Anatomy 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 210000005260 human cell Anatomy 0.000 description 5
• 230000004576 lipid-binding Effects 0.000 description 5
• 108010022197 lipoprotein cholesterol Proteins 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 230000008018 melting Effects 0.000 description 5
• 238000002844 melting Methods 0.000 description 5
• 208000010125 myocardial infarction Diseases 0.000 description 5
• 230000036470 plasma concentration Effects 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 230000001629 suppression Effects 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
• 206010001513 AIDS related complex Diseases 0.000 description 4
• 101710126783 Acetyl-hydrolase Proteins 0.000 description 4
• 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 4
• 235000005749 Anthriscus sylvestris Nutrition 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 208000024172 Cardiovascular disease Diseases 0.000 description 4
• 206010020772 Hypertension Diseases 0.000 description 4
• 102100035131 Lipopolysaccharide-binding protein Human genes 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 239000008186 active pharmaceutical agent Substances 0.000 description 4
• 230000010398 acute inflammatory response Effects 0.000 description 4
• 210000002945 adventitial reticular cell Anatomy 0.000 description 4
• 125000003368 amide group Chemical group 0.000 description 4
• 238000000149 argon plasma sintering Methods 0.000 description 4
• 238000010241 blood sampling Methods 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 230000002950 deficient Effects 0.000 description 4
• 230000003111 delayed effect Effects 0.000 description 4
• 238000004090 dissolution Methods 0.000 description 4
• 229940088679 drug related substance Drugs 0.000 description 4
• 238000005538 encapsulation Methods 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 150000007523 nucleic acids Chemical group 0.000 description 4
• 125000003729 nucleotide group Chemical group 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• 238000001543 one-way ANOVA Methods 0.000 description 4
• 108010028522 peptide 18A Proteins 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 238000001556 precipitation Methods 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 230000032258 transport Effects 0.000 description 4
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
• 239000005541 ACE inhibitor Substances 0.000 description 3
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 101800002011 Amphipathic peptide Proteins 0.000 description 3
• 206010002383 Angina Pectoris Diseases 0.000 description 3
• 102000004506 Blood Proteins Human genes 0.000 description 3
• 108010017384 Blood Proteins Proteins 0.000 description 3
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
• 208000004434 Calcinosis Diseases 0.000 description 3
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
• 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 3
• 208000035150 Hypercholesterolemia Diseases 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
• 239000008346 aqueous phase Substances 0.000 description 3
• 230000002308 calcification Effects 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 238000002983 circular dichroism Methods 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 230000009089 cytolysis Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 239000003651 drinking water Substances 0.000 description 3
• 235000020188 drinking water Nutrition 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 238000012377 drug delivery Methods 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 239000003925 fat Substances 0.000 description 3
• 235000019197 fats Nutrition 0.000 description 3
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 238000002523 gelfiltration Methods 0.000 description 3
• 238000003306 harvesting Methods 0.000 description 3
• 230000036571 hydration Effects 0.000 description 3
• 238000006703 hydration reaction Methods 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
• 239000007943 implant Substances 0.000 description 3
• 230000004968 inflammatory condition Effects 0.000 description 3
• YAFQFNOUYXZVPZ-UHFFFAOYSA-N liproxstatin-1 Chemical compound ClC1=CC=CC(CNC=2C3(CCNCC3)NC3=CC=CC=C3N=2)=C1 YAFQFNOUYXZVPZ-UHFFFAOYSA-N 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 239000004005 microsphere Substances 0.000 description 3
• 108020004707 nucleic acids Proteins 0.000 description 3
• 102000039446 nucleic acids Human genes 0.000 description 3
• 239000002773 nucleotide Substances 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 239000000816 peptidomimetic Substances 0.000 description 3
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
• 230000000704 physical effect Effects 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 230000037452 priming Effects 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 230000004141 reverse cholesterol transport Effects 0.000 description 3
• 230000000391 smoking effect Effects 0.000 description 3
• 238000010532 solid phase synthesis reaction Methods 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 238000005199 ultracentrifugation Methods 0.000 description 3
• OCLLVJCYGMCLJG-CYBMUJFWSA-N (2r)-2-azaniumyl-2-naphthalen-1-ylpropanoate Chemical compound C1=CC=C2C([C@@](N)(C(O)=O)C)=CC=CC2=C1 OCLLVJCYGMCLJG-CYBMUJFWSA-N 0.000 description 2
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
• BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 description 2
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 101150037123 APOE gene Proteins 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 2
• 229910017214 AsGa Inorganic materials 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
• 239000002083 C09CA01 - Losartan Substances 0.000 description 2
• 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• 101100216294 Danio rerio apoeb gene Proteins 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 2
• 241000023813 Isia Species 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• NAACPBBQTFFYQB-UHFFFAOYSA-N Linolsaeure-cholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCC=CCCCCC)C2 NAACPBBQTFFYQB-UHFFFAOYSA-N 0.000 description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
• 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
• 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 101100005882 Mus musculus Cel gene Proteins 0.000 description 2
• 101100289046 Mus musculus Lias gene Proteins 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
• RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 239000004264 Petrolatum Substances 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 2
• 206010058874 Viraemia Diseases 0.000 description 2
• GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000000853 adhesive Substances 0.000 description 2
• 230000001070 adhesive effect Effects 0.000 description 2
• 150000001447 alkali salts Chemical class 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
• 230000000489 anti-atherogenic effect Effects 0.000 description 2
• 210000002403 aortic endothelial cell Anatomy 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 150000001576 beta-amino acids Chemical class 0.000 description 2
• CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 2
• 239000003613 bile acid Substances 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 239000012503 blood component Substances 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 150000001840 cholesterol esters Chemical class 0.000 description 2
• NAACPBBQTFFYQB-XNTGVSEISA-N cholesteryl octadeca-9,12-dienoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCC=CCC=CCCCCC)C1 NAACPBBQTFFYQB-XNTGVSEISA-N 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
• 238000000205 computational method Methods 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 238000000113 differential scanning calorimetry Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 238000010494 dissociation reaction Methods 0.000 description 2
• 230000005593 dissociations Effects 0.000 description 2
• HOWGUJZVBDQJKV-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 description 2
• SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
• 239000000386 donor Substances 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 239000003480 eluent Substances 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000003292 glue Substances 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 229960000789 guanidine hydrochloride Drugs 0.000 description 2
• DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 229940095990 inderal Drugs 0.000 description 2
• 230000000053 inderal effect Effects 0.000 description 2
• 208000037797 influenza A Diseases 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• YOSHYTLCDANDAN-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2NN=NN=2)C(CCCC)=NC21CCCC2 YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 description 2
• 101150091094 lipA gene Proteins 0.000 description 2
• 229940089504 lopressor Drugs 0.000 description 2
• PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 description 2
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000000302 molecular modelling Methods 0.000 description 2
• 239000007922 nasal spray Substances 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
• RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 2
• 229940066842 petrolatum Drugs 0.000 description 2
• 235000019271 petrolatum Nutrition 0.000 description 2
• 239000002831 pharmacologic agent Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 2
• JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 2
• 239000011148 porous material Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000003244 pro-oxidative effect Effects 0.000 description 2
• 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 108091006082 receptor inhibitors Proteins 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 230000008439 repair process Effects 0.000 description 2
• 239000013557 residual solvent Substances 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• JBYXPOFIGCOSSB-UQGDGPGGSA-N rumenic acid Chemical compound CCCCCC\C=C/C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-UQGDGPGGSA-N 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000005204 segregation Methods 0.000 description 2
• 238000004904 shortening Methods 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 238000000527 sonication Methods 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 239000003451 thiazide diuretic agent Substances 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• IIYFAKIEWZDVMP-UHFFFAOYSA-N tridecane Chemical compound CCCCCCCCCCCCC IIYFAKIEWZDVMP-UHFFFAOYSA-N 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 230000000007 visual effect Effects 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
• PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• UKUVVAMSXXBMRX-UHFFFAOYSA-N 2,4,5-trithia-1,3-diarsabicyclo[1.1.1]pentane Chemical compound S1[As]2S[As]1S2 UKUVVAMSXXBMRX-UHFFFAOYSA-N 0.000 description 1
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
• CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 102000018619 Apolipoproteins A Human genes 0.000 description 1
• 108010027004 Apolipoproteins A Proteins 0.000 description 1
• 102000018655 Apolipoproteins C Human genes 0.000 description 1
• 108010027070 Apolipoproteins C Proteins 0.000 description 1
• 101100287942 Arabidopsis thaliana KEA1 gene Proteins 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 241000283725 Bos Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
• 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
• 101100471685 Caenorhabditis elegans ubq-2 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 101001026137 Cavia porcellus Glutathione S-transferase A Proteins 0.000 description 1
• 229940123150 Chelating agent Drugs 0.000 description 1
• 108010004103 Chylomicrons Proteins 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 102100036227 Cysteine and histidine-rich protein 1 Human genes 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 210000001956 EPC Anatomy 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 108010061435 Enalapril Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical group [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 101001026109 Gallus gallus Glutathione S-transferase Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 101000947448 Homo sapiens Cysteine and histidine-rich protein 1 Proteins 0.000 description 1
• 101000735376 Homo sapiens Protocadherin-8 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• 108010011942 LH Receptors Proteins 0.000 description 1
• 241000283986 Lepus Species 0.000 description 1
• 108010007859 Lisinopril Proteins 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
• 241001181114 Neta Species 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010071384 Peptide T Proteins 0.000 description 1
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
• 108010003541 Platelet Activating Factor Proteins 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920002367 Polyisobutene Polymers 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102100034958 Protocadherin-8 Human genes 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 239000004809 Teflon Substances 0.000 description 1
• 229920006362 Teflon® Polymers 0.000 description 1
• 241000724822 Teia Species 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229940077422 accupril Drugs 0.000 description 1
• 229960002122 acebutolol Drugs 0.000 description 1
• 229940062352 aceon Drugs 0.000 description 1
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
• PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 230000009692 acute damage Effects 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 239000000332 adrenergic beta-1 receptor antagonist Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229940077927 altace Drugs 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• LSTJLLHJASXKIV-UHFFFAOYSA-N amino hexanoate Chemical compound CCCCCC(=O)ON LSTJLLHJASXKIV-UHFFFAOYSA-N 0.000 description 1
• 229960002684 aminocaproic acid Drugs 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 239000002280 amphoteric surfactant Substances 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 206010002022 amyloidosis Diseases 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 229940058087 atacand Drugs 0.000 description 1
• METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
• 229960002274 atenolol Drugs 0.000 description 1
• 230000036523 atherogenesis Effects 0.000 description 1
• 229940000201 avapro Drugs 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 229960004530 benazepril Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229960004324 betaxolol Drugs 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000001851 biosynthetic effect Effects 0.000 description 1
• 229960002781 bisoprolol Drugs 0.000 description 1
• VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 239000003618 borate buffered saline Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 238000005282 brightening Methods 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
• 239000000920 calcium hydroxide Substances 0.000 description 1
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
• 229960000932 candesartan Drugs 0.000 description 1
• SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
• 229940097633 capoten Drugs 0.000 description 1
• 229960000830 captopril Drugs 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 229960001222 carteolol Drugs 0.000 description 1
• LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 239000003093 cationic surfactant Substances 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 150000001879 copper Chemical class 0.000 description 1
• OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 229940097499 cozaar Drugs 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• JDPQWHLMBJZURR-UHFFFAOYSA-N decan-5-one Chemical compound CCCCCC(=O)CCCC JDPQWHLMBJZURR-UHFFFAOYSA-N 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 238000005202 decontamination Methods 0.000 description 1
• 230000003588 decontaminative effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000021045 dietary change Nutrition 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
• 229940074619 diovan Drugs 0.000 description 1
• MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• UFBNRDHQYCQOII-UHFFFAOYSA-N docosan-11-one Chemical compound CCCCCCCCCCCC(=O)CCCCCCCCCC UFBNRDHQYCQOII-UHFFFAOYSA-N 0.000 description 1
• 230000035622 drinking Effects 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 229960000873 enalapril Drugs 0.000 description 1
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000007071 enzymatic hydrolysis Effects 0.000 description 1
• 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
• 235000012041 food component Nutrition 0.000 description 1
• 239000005428 food component Substances 0.000 description 1
• 150000003948 formamides Chemical class 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 229960002490 fosinopril Drugs 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 238000007306 functionalization reaction Methods 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 210000004211 gastric acid Anatomy 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 238000009499 grossing Methods 0.000 description 1
• 229960004198 guanidine Drugs 0.000 description 1
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 238000005534 hematocrit Methods 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• 230000023597 hemostasis Effects 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 239000000852 hydrogen donor Substances 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• 238000007327 hydrogenolysis reaction Methods 0.000 description 1
• 230000005661 hydrophobic surface Effects 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 229960001195 imidapril Drugs 0.000 description 1
• KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 239000013546 insoluble monolayer Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229960002198 irbesartan Drugs 0.000 description 1
• OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 238000010983 kinetics study Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 229960001632 labetalol Drugs 0.000 description 1
• WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
• 229940096773 levatol Drugs 0.000 description 1
• 125000000403 lignoceroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 102000019758 lipid binding proteins Human genes 0.000 description 1
• 108091016323 lipid binding proteins Proteins 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 229960002394 lisinopril Drugs 0.000 description 1
• RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
• 235000021142 long-term diet Nutrition 0.000 description 1
• 229960004773 losartan Drugs 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 102000014650 luteinizing hormone receptor activity proteins Human genes 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229940103179 mavik Drugs 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
• 229960002237 metoprolol Drugs 0.000 description 1
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
• 229940099246 mevacor Drugs 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 229940118178 monopril Drugs 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• 229960004255 nadolol Drugs 0.000 description 1
• VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 108010024603 neurotensin mimic 1 Proteins 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 238000006902 nitrogenation reaction Methods 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 238000001807 normal pulse voltammetry Methods 0.000 description 1
• 230000000444 normolipidemic effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 229940038384 octadecane Drugs 0.000 description 1
• TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000005416 organic matter Substances 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000001236 palmitoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 229960002035 penbutolol Drugs 0.000 description 1
• KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
• FEDSNBHHWZEYTP-ZFQYHYQMSA-N penbutolol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1.CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 FEDSNBHHWZEYTP-ZFQYHYQMSA-N 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229960002582 perindopril Drugs 0.000 description 1
• IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
• IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 239000003209 petroleum derivative Substances 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229960002508 pindolol Drugs 0.000 description 1
• 230000007505 plaque formation Effects 0.000 description 1
• 239000003495 polar organic solvent Substances 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920002635 polyurethane Polymers 0.000 description 1
• 239000004814 polyurethane Substances 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 239000003223 protective agent Substances 0.000 description 1
• 230000009993 protective function Effects 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 230000022558 protein metabolic process Effects 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 229960003401 ramipril Drugs 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000004153 renaturation Methods 0.000 description 1
• 239000010979 ruby Substances 0.000 description 1
• 229910001750 ruby Inorganic materials 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 150000004671 saturated fatty acids Chemical class 0.000 description 1
• 235000003441 saturated fatty acids Nutrition 0.000 description 1
• 229940082552 sectral Drugs 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 210000003291 sinus of valsalva Anatomy 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 238000010183 spectrum analysis Methods 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000005728 strengthening Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940108485 tenormin Drugs 0.000 description 1
• ZEKPOTWCBTUBEB-UHFFFAOYSA-N tetradecan-7-one Chemical compound CCCCCCCC(=O)CCCCCC ZEKPOTWCBTUBEB-UHFFFAOYSA-N 0.000 description 1
• HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
• RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
• UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 238000009210 therapy by ultrasound Methods 0.000 description 1
• 238000001757 thermogravimetry curve Methods 0.000 description 1
• WRCITXQNXAIKLR-UHFFFAOYSA-N tiadenol Chemical compound OCCSCCCCCCCCCCSCCO WRCITXQNXAIKLR-UHFFFAOYSA-N 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 229960004605 timolol Drugs 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229960002051 trandolapril Drugs 0.000 description 1
• 238000013271 transdermal drug delivery Methods 0.000 description 1
• 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000012250 transgenic expression Methods 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
• 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 229960004699 valsartan Drugs 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 229940063670 visken Drugs 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1